{
    "url_original": "https://www.wsj.com/articles/lower-omicron-efficacy-delayed-fda-review-on-pfizer-shot-in-kids-under-5-11645192800?mod=politics_lead_pos7",
    "url": "lower-omicron-efficacy-delayed-fda-review-on-pfizer-shot-in-kids-under-5-11645192800",
    "title": "Pfizer’s Covid-19 Vaccine for Kids Isn’t Working Well Against Omicron So Far, Delaying FDA Review",
    "sub_head": "Regulators and drugmaker opted to finish testing before weighing vaccine’s performance in that age group after early signs of weakness against the variant",
    "category_1": "Health",
    "time": "2022-02-18 09:18:00",
    "body": "U.S. health regulators delayed their review of  Pfizer Inc.’s  Covid-19 vaccine in children under 5 years old because the initial two-dose series so far wasn’t working well against the Omicron variant during testing, people familiar with the decision said.<br />An early look at data showed the vaccine to be effective against the Delta variant during testing while that was the dominant strain, but some vaccinated children developed Covid-19 after Omicron emerged, the people said."
}